Tarsus Pharmaceuticals Inc Ordinary Shares TARS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
-
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
-
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
-
Tarsus to Participate in Upcoming Investor Conferences
-
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
-
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
-
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
-
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Trading Information
- Previous Close Price
- $72.08
- Day Range
- $67.65–71.71
- 52-Week Range
- $53.89–91.53
- Bid/Ask
- $67.76 / $68.95
- Shares Outstanding
- 46.79M
- Market Cap
- $3.19B
- Volume/Avg
- 556,619 / 835,473
Key Statistics
- Price/Earnings (Normalized)
- 538.26
- Price/Sales
- 4.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 370
- Website
- https://www.tarsusrx.com
Valuation
|
Metric
|
TARS
|
|---|---|
Price/Earnings (Normalized) | 538.26 |
Price/Book Value | 8.51 |
Price/Sales | 4.83 |
Price/Cash Flow | 1,392.46 |
Price/Earnings
TARS
Financial Strength
|
Metric
|
TARS
|
|---|---|
Quick Ratio | 3.12 |
Current Ratio | 3.20 |
Interest Coverage | −5.74 |
Quick Ratio
TARS
Profitability
|
Metric
|
TARS
|
|---|---|
Return on Assets (Normalized) | 0.96% |
Return on Equity (Normalized) | 1.56% |
Return on Invested Capital (Normalized) | −0.49% |
Return on Assets
TARS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xH%?>&& | LOCK|dZMD | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^<h%wT | LOCK|D^Rc | $83B | |||
| Moderna Inc
MRNA
| LOCK|jdX>#&d | LOCK|#j | $80B | |||
| argenx SE ADR
ARGX
| LOCK|q&S%jP | LOCK|gZs | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X%#S!# | LOCK|^rh | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^wlRM$^ | LOCK|Lqb<k | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!h$b@#q? | LOCK|njz?@ | $28B | |||
| Incyte Corp
INCY
| LOCK|Fgw#YmC | LOCK|Wt | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!c&>!V | LOCK|dZ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<FjHz^@ | LOCK|Cm% | $14B |
United States